Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622917 | 0.75 | ALDH1A1 (0.30) | ALDH1A1CYP2C19 | |
| SCHEMBL28738653 | 0.71 | LMNA (0.35) | LMNAALOX15BLMPMP22ALDH1A1 | |
| SCHEMBL7306493 | 0.69 | — | — | |
| SCHEMBL15374309 | 0.69 | — | — | |
| SCHEMBL276116 | 0.69 | — | — | |
| SCHEMBL1255904 | 0.69 | LMNA (0.33) | LMNAALOX15BLMPMP22ALDH1A1 | |
| SCHEMBL5633427 | 0.69 | ARG1 (0.33) | LMNAALOX15BLMPMP22ALDH1A1 | |
| SCHEMBL15374310 | 0.69 | — | — | |
| SCHEMBL2170002 | 0.69 | — | — | |
| SCHEMBL28346567 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452990-B2 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2008-11-18 | — | — | US | disclosed |
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | LUPIN LIMITED (IN) | 2006-06-22 | — | — | US | disclosed |
| EP-1575913-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES | Lupin Limited (IN) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058695-A1 | NOVEL INTERMEDIATES FOR SYNTHESIS OF CEPHALOSPORINS AND PROCESS FOR PREPARATION OF SUCH INTERMEDIATES | LUPIN LIMITED (IN) | 2004-07-15 | — | — | WO | disclosed |
| WO-2003059908-A1 | NOVEL THIOESTER DERIVATIVES AND PROCESS FOR PREPARATION OF CEPHALOSPORIN | ORCHID CHEMICALS & PHARMACEUTICALS LIMITED (IN) | 2003-07-24 | — | — | WO | disclosed |
| US-5945532-A | Method for manufacture of cephalosporin and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1999-08-31 | — | — | US | disclosed |
| US-5856502-A | Method for manufacture of cephalosporin and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1999-01-05 | — | — | US | disclosed |
| US-5739346-A | Dimethyl formiminium chloride chlorosulphate derivatives useful as intermediates for producing cephalosporins | LUPIN LABORATORIES LIMITED (IN) | 1998-04-14 | — | — | US | disclosed |
| EP-0791596-A1 | Method for manufacture of cephalosporins and intermediates thereof | LUPIN LABORATORIES LIMITED (IN) | 1997-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135761-A1 | 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate; cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, etc | CYP2F1, CYP2W1, CYP4F11 | LMNA 4551/4885ALOX15 1285/4885BLM 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.